To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Open-Label Placebo Administration in Elderly Patients With Symptomatic Knee Osteoarthritis

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
July 2022

Open-Label Placebo Administration in Elderly Patients With Symptomatic Knee Osteoarthritis

Vol: 270| Issue: 1| Number:2| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Open-Label Placebo Administration Decreases Pain in Elderly Patients With Symptomatic Knee Osteoarthritis - A Randomized Controlled Trial

Front Psychiatry. 2022 01-May;():. 10.3389/fpsyt.2022.853497

Contributing Authors:
E Olliges S Stroppe A Haile F Reiß M Malhis SA Funke K Meissner

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty-one patients with knee osteoarthritis were randomized to receive an open-label placebo with verbal suggestions indicating pain relief (n=21) or mood improvement (n=21), or no treatment (n=19). The primary outcomes of interest included knee pain and function (Numeric Rating Scale [NRS]; Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]). Secondary outcomes of interest inc...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue